Anti-VEGF antibodies
AssigneeGenentech, Inc.
InventorsManuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
Life of this patent
Estimating the term…
Abstract
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Claims2
A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a Kd value of no more than about 1×10−8M, said humanized anti-VEGF antibody comprising a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.
A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a Kd value of no more than about 1×10−8M, said humanized anti-VEGF antibody comprising a heavy chain variable domain sequence of SEQ ID NO:7 and a light chain variable domain sequence of SEQ ID NO:8.
Dependencies are inferred from the claim text.